

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司*

(Incorporated in Bermuda with limited liability)
(於百慕達註冊成立之有限公司)
(Stock Code 股份代號: 00512)

15 February 2024

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Grand Pharmaceutical Group Limited (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.grandpharma.cn and the HKEXnews website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications; (ii) need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications; and (iii) the Company will send the Actionable Corporate Communications^(Note) in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete the enclosed Reply Form and send it to the Share Registrar or send an email to grandpharma.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully, By order of the Board Grand Pharmaceutical Group Limited Dr. Tang Weikun Chairman

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07條,遠大醫藥集團有限公司*(「**公司**」)謹此通知 閣下,公司已採用以電子方式發布公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用);(c)會議通知;(d)上市文件;(e)通函和(f)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.grandpharma.cn 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到最新的公司通訊,公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者, 閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前 閣下將(i)無法收到任何有關發布公司通訊的通知 (ii)需要主動查看公司網站和披露易網站以留意公司通訊的發布;及(iii)本公司未來將以印刷本形式發送可供採取行動的公司通訊 (^{fit)}。

若 閣下希望收取未來公司通訊之印刷本,請填妥回條或發送電子郵件至 <u>grandpharma.ecom@computershare.com.hk</u>,並註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)期間致電股份過戶處 (852)2862 8688 查詢。

承董事會命 遠大醫藥集團有限公司* 唐緯坤博士 主 主 謹的

2024年2月15日

REPLY	FORM	回條
-------	-------------	----

Computershare Hong Kong Investor Services Limited (the "Share Registrar") $\quad \mathfrak{Y}$: 香港中央證券登記有限公司 (「股份過戶處」)

17M Floor, Hopewell Centre

183 Oueen's Road East, Wan Chai, Hong Kong

香港灣仔皇后大道東 183 號 合和中心 17M 樓

(Please <u>choose ONLY ONE</u> of the options below) (請從以下選項中**只選擇其中一項**)

Personalized QR Code 專屬二維碼

Option 1: Provide your email address for receipt of future Corporate Communications# of

the Company via electronic dissemination by scanning your personalized QR code

掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式 選項1: 發佈的未來公司通訊#

> You are **NOT required** to return this Reply Form if you choose Option 1. 如選擇了選項 1, 閣下無須交回本回條。

"Company") via electronic dissemination	in writing for receipt of future Corporate Con 子郵件地址·以確保收到以下上市公司(「本 Name of the listed company 上 Grand Pharmaceutic 遠大醫藥集團有限公	公司」)通過電子方式發佈的未來公司通訊# 市公司名稱: cal Group Limited	
Email address 電郵地址: (Note 3 / 附註 3)	超八國东 宋国万联A		
Option 3: I/we hereby request for receipt of Corpora 本人/吾等現要求收取公司通訊 [#] 印刷本(opy and noted that this instruction is valid only for o	,	(Note 5)
Signature(s): (Note 1) 簽名:(附註 1)	Contact number: 聯絡電話號碼:	Date: 日期:	
Notes 附註: 1. Please complete all your details clearly. If your shares are held in joint n 請清楚填安 圖下之所有資料。如屬聯名股東,則本回線須由所有壽名. 2. Any Reply Form with no signature or otherwise incorrectly completed will 任何回條若未有簽署或在其他方面填寫不正確,則本回條將會作簽。 3. If the Company does not receive a functional enail address in your reply, 如公司沒有收到 圖下的有效電子郵件地址。圖下將無法收到角關發布。 4. If you provide more than one email address by QR code, email, reply form 如 圖下海過一級經一級經過一級經過一級經過一級經過一級經過一級經過一級經過一級經過一級經過	股東聯合簽署·方為有效。 be void. vou will be unable to receive notifications regarding the publica Co司通訊的通知。 and/or other means, only the latest one email address provided	ttion of Corporate Communications ^e . will be registered.	

- 5. If you mark "♥" in the box in Option 3, no email address will be registered and only Corporate Communications# in printed form will be received.

 如 阁下在選項3方格內劃上「▼」號·將不會有電子郵件地址被登記·只會收取公司通訊#的印刷本。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form. 為免存疑·在本回條上的任何額外指示·本公司將不予處理。
- For identification purposes only 僅供識別
- Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form. 除某另看证明。公司通讯分析公司已经出版者务证比较其任何證券的结构,参照或接取行動的任何文件,其中包括但不限於年報、中期報告、會議通告、通過及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- (ii)
- **収集個人資料智明****Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordnance, Chapter 486 of the Laws of Hong Kong ("PDPO").
 *本管明中所指的"個人資料」與香港法例第 486章 【個人資料 (私膳)條例》(「《私膳條例》」)中「個人資料」的涵義相同。
 Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company, Your supply of Personal Data to the Company is on a volumery basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.
 圖下於本自經所提供的個人資料無用於(包括但不限於)有關本公司以電子方式發佈公司通訊"及就 圖下持有的公司證券有關的其他事宜上與 圖下聯絡。圖下是自願向本公司提供個人資料。若 圖下未能提供足夠資料、本公司可能無法處理 圖下在本回條上所述的指示及/或要求。
 Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
 父司司就任何所說初時別年建筑在法例策度及情景下,"將 圖下的個人資料接來開發給公司的附屬公司、股份過戶處、及/或其他公司或團體・並將在適當期間保留該等個人資料作核實及紀錄用途。
 You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.ht.

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司

Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us. No postage is necessary if posted in Hong Kong.

> 閣下寄回此回條時・請將郵寄標籤剪貼於信封上 如在本港投寄 · 閣下無需支付郵費或貼上郵票